ASXL1, located on chromosomal region 20q11, is mutated in ≈20% of patients with MDS, ≈35% of MPN, ≈30% of secondary AML, ≈7% of the de novo AML and up to 40% of patients with MDS/MPN[2, 13]. Here, ASXL1 is linked to myeloproliferative neoplasm.